论文部分内容阅读
糖原磷酸化酶同工酶脑型(GPBB)是糖原分解的关键酶,最早在实验室因缺血而被检测到。目前,GPBB成为最具潜质的心肌损伤生物标记,其在胸痛开始的1~4 h内浓度开始增加,并且释放本质上依赖于心肌缺血损伤。对比其他已知心肌标志物,GPBB对于诊断冠状动脉综合征中不同形式的心肌缺血损伤具有高度敏感性和特异性。近期随着酶联免疫吸附法、多种生物标记技术测定GPBB含量的应用,GPBB还可能应用于其他原因所致的心肌损害。
Glycogen phosphorylase isoenzymes brain (GPBB) is the key enzyme for glycogenolysis, the earliest in the laboratory was detected due to ischemia. At present, GPBB is the most potential biomarker for myocardial injury, and its concentration begins to increase within 1 to 4 h of onset of chest pain and release is essentially dependent on myocardial ischemic injury. In contrast to other known cardiac markers, GPBB is highly sensitive and specific for the diagnosis of various forms of myocardial ischemia in coronary syndromes. With the recent enzyme-linked immunosorbent assay, a variety of biomarkers to determine the application of GPBB content, GPBB may also be applied to other causes of myocardial damage.